N/A N=76 Effect of VarIthena on Wound Healing in Venous Leg Ulcers (VLU)
Venous Leg Ulcer
Primary: Change From Baseline in Wound Perimeter — 29.36; 43.64 mm
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=60 Atovaquone for Treatment of COVID-19
COVID-19
Primary: Primary Analysis — -1.906; 2.629; 4.073 log 10 (copies/mL) — p=0.170
Phase 3 N=228 A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.
Allergic Conjunctivitis
Primary: Ocular Itching — 1.609; 1.886; 2.219; 1.750 units on a scale — p=< 0.0001
Phase 2 N=23 PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers
Neuroendocrine Tumors · Carcinoma, Small Cell Lung · Neuroendocrine Carcinoma
Primary: Phase 1: Maximum Tolerated Dose of PEN-221 and Recommended Phase 2a Dose (RP2D) — 18.0 mg
Phase 2 N=104 Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)
ALK-positive Advanced NSCLC
Primary: Confirmed Objective Response Rate (ORR) in the Main Cohort of the Refractory Expansion Part — 34.0 percentage of participants
N/A N=1,605 XIENCE 28 USA Study
Bleeding Disorder · Ischemic Stroke · Hemorrhagic Stroke
Primary: Percentage of Participants With Composite Rate of All Death or All Myocardial Infarction (MI) (Modified Academic Research Consortium [ARC]), by Propensity Score Quintile…
Phase 2 N=120 A Study of Acute Myocardial Infarction Using FDY-5301
Acute Myocardial Infarction · STEMI
Primary: Arrhythmias of Interest, 48 Hours (Overall) — 0; 0; 0; 0 participants
N/A N=135 Clinical Evaluation of Senofilcon A Contact Lenses Using a Novel Manufacturing Technology
Visual Acuity
Primary: Overall CLUE Comfort — 60.9; 65.1 unit on a scale
Phase 2 N=165 Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The PEARL Study)
Dry Eye Disease
Primary: Schirmer's Test Score at Day 1 — 9.0; 17.5; 19.6; 3.0 mm
Phase 2 N=610 An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects
Asthma
Primary: Pre-dose Morning FEV1 at Week 8 - Change From Baseline — 0.021; 0.090; 0.070; -0.023 Litres — p=0.567
N/A N=9 The Effectiveness of Participation-focused Interventions on Body Functions of Youth With Physical Disabilities
Cerebral Palsy · Spina Bifida · Muscular Dystrophies
Primary: Change in Behavioral Assessment System for Children — 54.73; -3.35; -0.05; 64.38 fixed effects estimate
Phase 1 N=6 Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome
Adult T-Cell Lymphoma/Leukemia · Sezary Syndrome · Mycosis Fungoides
Primary: Maximum Tolerated Dose (MTD) of Recombinant Human Interleukin 15 (IL-15) (rhIL-15) — 2 mcg/kg/day
N/A N=14 A Comparison of LASIK Outcomes Using Two Femtosecond Lasers
Myopia · Astigmatism
Primary: ETDRS Uncorrected Visual Acuity — 5; 5 Eyes
Phase 2 N=70 Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)
Colorectal Cancer
Primary: Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 Assessed by Investigator — 7.1 percentage (%) of participants — p=0.2721
Phase 3 N=361 A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea
Papulopustular Rosacea
Primary: Percentage of Participants Achieving an IGA Score of Clear or Almost Clear From Baseline at Week 12 — 43.5; 16.1 Percentage of Participants